Please try another search
Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Malcolm Rowland | - | - | Chair of Simcyp Scientific Advisory Board |
William F. Feehery | 51 | 2019 | CEO & Director |
James E. Cashman | 68 | 2018 | Independent Chairman of the Board |
Matthew M. Walsh | 55 | 2017 | Independent Director |
Nancy Killefer | 69 | 2021 | Independent Director |
Rosemary A. Crane | 62 | 2022 | Independent Director |
Donald E. Mager | - | - | Member of Simcyp Scientific Advisory Board |
Jennifer B. Dressman | - | 2017 | Member of Simcyp Scientific Advisory Board |
Stephen M. McLean | - | 2013 | Independent Director |
David Spaight | - | 2022 | Independent Director |
Yuichi Sugiyama | - | - | Member of Simcyp Scientific Advisory Board |
Noriko Okudaira | - | 2019 | Senior Consultant & Member of Simcyp Scientific Advisor Board |
J Brian Houston | - | - | Member of Simcyp Scientific Advisory Board |
Geoff Tucker | - | - | Member of Simcyp Scientific Advisory Board |
Lawrence J. Lesko | - | 2015 | Member of Simcyp Scientific Advisory Board |
Eran Broshy | 64 | 2022 | Independent Director |
Cynthia L. Collins | 65 | 2021 | Independent Director |
Frederic Yves Bois | - | 2019 | Senior Scientific Advisor, Head of Mechanistic Modeling & Member of Simcyp Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review